Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.

by Birgit Engesæter, Olav Engebraaten, Vivi Ann Flørenes, Gunhild Mari Mælandsmo
Published 2012-01-01

High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

by Gry Irene Magnussen, Ruth Holm, Elisabeth Emilsen, Anne Katrine Ree Rosnes, Ana Slipicevic, Vivi Ann Flørenes
Published 2012-01-01

Collateral Expression of Proangiogenic and Tumorigenic Properties in Intestinal Epithelial Cell Variants Selected for Resistance to Anoikis

by Janusz Rak, Yoshihiro Mitsuhashi, Cap Sheehan, Julia K. Krestow, Vivi Ann Florenes, Jorge Filmus, Robert S. Kerbel
Published 1999-04-01

Soluble AXL as a marker of disease progression and survival in melanoma.

by Karine Flem-Karlsen, Marta Nyakas, Inger Nina Farstad, Erin McFadden, Patrik Wernhoff, Kari Dolven Jacobsen, Vivi Ann Flørenes, Gunhild Mari Mælandsmo
Published 2020-01-01

Candidate Genes for Testicular Cancer Evaluated by In Situ Protein Expression Analyses on Tissue Microarrays

by Rolf I. Skotheim, Vera M. Abeler, Jahn M. Nesland, Sophie D. Fosså, Ruth Holm, Urs Wagner, Vivi Ann Flørenes, Nina Aass, Olli P. Kallioniemi, Ragnhild A. Lothe
Published 2003-09-01

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

by Vivi Ann Flørenes, Karine Flem-Karlsen, Erin McFadden, Inger Riise Bergheim, Vigdis Nygaard, Vegard Nygård, Inger Nina Farstad, Geir Frode Øy, Elisabeth Emilsen, Karianne Giller-Fleten, Anne Hansen Ree, Kjersti Flatmark, Hans Petter Gullestad, Robert Hermann, Truls Ryder, Patrik Wernhoff, Gunhild Mari Mælandsmo
Published 2019-07-01